Yahoo Finance29d
FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis
LPCN 1148, an oral prodrug of bioidentical testosterone, was recently studied in a proof-of-concept (POC) Phase 2 study in patients with decompensated cirrhosis. Treatment with LPCN 1148 in the ...
Business Insider28d
Lipocine's LPCN 1148 Gets Fast Track Status To Treat Sarcopenia In Decompensated Cirrhosis Patients
(RTTNews) - Lipocine Inc. (LPCN), a biopharmaceutical company, Tuesday said that the U.S. Food and Drug Administration or FDA has granted Fast Track Designation to LPCN 1148, the company's drug ...